Download PDF
Horm Metab Res 2022; 54(09): 593-603
DOI: 10.1055/a-1897-5992
Original Article: Endocrine Care

Homocysteine and the Mortality of Critically Ill Patients: A Meta-Analysis

Fawei Yuan
1   Department of Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China
2   Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, China
,
Kun Zheng
1   Department of Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China
2   Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi, Hubei, China
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Prevalence of hyperhomocysteinemia (HHcy) is high in critically ill patients. However, the association between serum homocysteine level and outcomes of the critically ill patients remains unknown. We performed a meta-analysis of cohort studies to comprehensively evaluate the above association. Relevant cohort studies were identified by search of electronic databases including PubMed, Embase, Web of Science, Wanfang, and CNKI from the inception of the databases to February 5, 2022. A randomized-effect model incorporating the possible between-study heterogeneity was used to pool the results. Overall, 16 cohorts with 1663 critically ill patients who were admitted to the intensive care unit (ICU) were involved in the meta-analysis. Pooled results showed that compared to non-survivors of the critical illnesses, survivors had significantly lower serum level of Hcy at ICU admission [mean difference (MD): –3.42 μmol/l, 95% confidence interval (CI): –5.89 to 0.94, p=0.007; I2=86%]. Subgroup analysis showed that the difference of Hcy between survivors and non-survivors was significant in Asian patients (MD: –8.17 μmol/l, p<0.001), but not in non-Asians (MD: 0.30 μmol/l, p=0.62; p for subgroup difference<0.001). Moreover, meta-analysis with seven cohorts, all including Chinese patients, showed that HHcy at ICU admission was independently associated with a higher risk of all-cause mortality in critically ill patients (odds ratio: 2.99, 95% CI: 2.26 to 3.97, p<0.001; I2=69%). A higher serum level of Hcy at ICU admission may be associated with an increased risk of all-cause mortality in critically ill patients, particularly in the Chinese population.

Key words

homocysteine - hyperhomocysteinemia - critically ill - mortality - meta-analysis


Publication History

Received: 05 May 2022

Accepted after revision: 27 June 2022

Article published online:
07 September 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Koklesova L, Mazurakova A, Samec M. et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J 2021; 1-29
    PubMedGoogle Scholar
  • 2 Herrmann W, Herrmann M. The controversial role of HCY and vitamin B deficiency in cardiovascular diseases. Nutrients 2022; 14: 1412
    CrossrefPubMedGoogle Scholar
  • 3 Kumar A, Palfrey HA, Pathak R. et al. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond) 2017; 14: 78
    CrossrefPubMedGoogle Scholar
  • 4 Lazzerini PE, Capecchi PL, Selvi E. et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007; 6: 503-509
    CrossrefPubMedGoogle Scholar
  • 5 Finch JM, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Hematol Disord Drug Targets 2010; 10: 241-245
    CrossrefPubMedGoogle Scholar
  • 6 Kaplan P, Tatarkova Z, Sivonova MK. et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems. Int J Mol Sci 2020; 21: 7698
    CrossrefPubMedGoogle Scholar
  • 7 Selhub J, Jacques PF, Bostom AG. et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev 2000; 28: 117-145
    PubMedGoogle Scholar
  • 8 Zeng Y, Li FF, Yuan SQ. et al. Prevalence of hyperhomocysteinemia in China: an updated meta-analysis. Biology (Basel) 2021; 10: 959
    PubMedGoogle Scholar
  • 9 Paganelli F, Mottola G, Fromonot J. et al. Hyperhomocysteinemia and cardiovascular disease: is the adenosinergic system the missing link?. Int J Mol Sci 2021; 22: 1690
    CrossrefPubMedGoogle Scholar
  • 10 Holmen M, Hvas AM, Arendt JFH. Hyperhomocysteinemia and ischemic stroke: a potential dose-response association - a systematic review and meta-analysis. TH Open 2021; 5: e420-e437
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Zhou F, Chen S. Hyperhomocysteinemia and risk of incident cognitive outcomes: an updated dose-response meta-analysis of prospective cohort studies. Ageing Res Rev 2019; 51: 55-66
    CrossrefPubMedGoogle Scholar
  • 12 Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 2006; 136: 1726S-1730S
    CrossrefPubMedGoogle Scholar
  • 13 Mizock BA. Homocysteine and critical illness. Crit Care Med 2000; 28: 1229-1230
    CrossrefPubMedGoogle Scholar
  • 14 Salemi G, Gueli MC, D’Amelio M. et al. Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurol Sci 2009; 30: 361-364
    CrossrefPubMedGoogle Scholar
  • 15 Yuzbasioglu MF, Ozkaya M, Cakal E. et al. Changes in plasma levels of homocysteine in patients with acute pancreatitis. JOP 2008; 9: 357-361
    PubMedGoogle Scholar
  • 16 Esse R, Barroso M, Tavares de Almeida I. et al. The contribution of homocysteine metabolism disruption to endothelial dysfunction: state-of-the-art. Int J Mol Sci 2019; 20: 867
    CrossrefPubMedGoogle Scholar
  • 17 Schindler K, Zauner C, Buchmayer H. et al. High prevalence of hyperhomocysteinemia in critically ill patients. Crit Care Med 2000; 28: 991-995
    CrossrefPubMedGoogle Scholar
  • 18 Stoiser B, Thalhammer F, El-Menyawi I. et al. Homocysteine and laminin are not prognostic markers in patients with septic inflammatory response syndrome. Clin Diagn Lab Immunol 2000; 7: 119-121
    CrossrefPubMedGoogle Scholar
  • 19 Coelho Neto A, Azevedo RP, Santos MB. et al. Homocysteine plasma levels as a marker of clinical severity in septic patients. Rev Bras Ter Intensiva 2010; 22: 327-332
    PubMedGoogle Scholar
  • 20 Ploder M, Kurz K, Spittler A. et al. Early increase of plasma homocysteine in sepsis patients with poor outcome. Mol Med 2010; 16: 498-504
    CrossrefPubMedGoogle Scholar
  • 21 Tsantes A, Tsangaris I, Nikolopoulos G. et al. The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis. Minerva Anestesiol 2010; 76: 787-794
    PubMedGoogle Scholar
  • 22 Feng HY, Li WW. Association between the level of homocysteine and in-hospital death in elderly patients with pulmonary embolism. J Chin Pract Diagn Ther 2015; 29: 491-493
    PubMedGoogle Scholar
  • 23 Chen YQ, Xiao Y, Hu DB. et al. Effect of homocysteine and cystatin levels of the prognosis of COPD patients with respiratory failure. Chin J Coal Indus Med 2020; 23: 293-298
    PubMedGoogle Scholar
  • 24 Niu J. Diagnostic value of serum cTnI, HCY and PCT in severity of multiple trauma patients and their relationship with prognosis. Chin J Emerg Resusc Disaster Med 2020; 15: 326-330
    PubMedGoogle Scholar
  • 25 Chen W, Li Y, Wu YH. et al. The evaluation value of serum homocysteine level for the prognosis of patients with sepsis. Chin J Clin Med 2021; 13: 73-75
    PubMedGoogle Scholar
  • 26 Meng W, Tian W. Associations of homocysteine, procalcitonin, and D-dimer levels with severity and prognosis of patients with multiple trauma. Clin Lab 2022; 68 DOI: 10.7754/Clin.Lab.2021.210525.
    CrossrefPubMedGoogle Scholar
  • 27 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
    Google Scholar
  • 28 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
    CrossrefPubMedGoogle Scholar
  • 29 Higgins J, Thomas J. Chandler et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
    PubMedGoogle Scholar
  • 30 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
    PubMed
  • 31 Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
    PubMedGoogle Scholar
  • 32 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
    Google Scholar
  • 33 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
    Google Scholar
  • 34 Rahmani A, Hatefi M, Dastjerdi MM. et al. Correlation between serum homocysteine levels and outcome of patients with severe traumatic brain injury. World Neurosurg 2016; 87: 507-515
    CrossrefPubMedGoogle Scholar
  • 35 Bernstein JE, Savla P, Dong F. et al. Inflammatory markers and severity of intracerebral hemorrhage. Cureus 2018; 10: e3529
    PubMedGoogle Scholar
  • 36 Wexler O, Gough MS, Morgan MAM. et al. Methionine metabolites in patients with sepsis. J Intensive Care Med 2018; 33: 37-47
    CrossrefPubMedGoogle Scholar
  • 37 Li HD, Xing B. Relation among homocysteine, severity and prognosis of acute pancreatitis. Chin Med 2020; 15: 721-725
    PubMedGoogle Scholar
  • 38 Liu M, Xing B. The effect of serum homocysteine level on septic patients with acute kidney injury. Chin J Emerg Resusc Disaster Med 2021; 16: 275-278
    PubMedGoogle Scholar
  • 39 Zhang N, Shi F, Liang H. et al. The feasibility of using Hcy, CRP, and Cys-C to analyze AMI patients’ disease conditions and prognoses. Am J Transl Res 2021; 13: 2724-2730
    PubMedGoogle Scholar
  • 40 Molina-Lopez J, Florea D, Quintero-Osso B. et al. Pyridoxal-5’-phosphate deficiency is associated with hyperhomocysteinemia regardless of antioxidant, thiamine, riboflavin, cobalamine, and folate status in critically ill patients. Clin Nutr 2016; 35: 706-712
    CrossrefPubMedGoogle Scholar
  • 41 Hou CT, Wu YH, Huang PN. et al. Higher plasma pyridoxal 5’-phosphate is associated with better blood glucose responses in critically ill surgical patients with inadequate vitamin B-6 status. Clin Nutr 2011; 30: 478-483
    CrossrefPubMedGoogle Scholar
  • 42 Gori AM, Sofi F, Marcucci R. et al. Association between homocysteine, vitamin B(6) concentrations and inflammation. Clin Chem Lab Med 2007; 45: 1728-1736
    PubMedGoogle Scholar
  • 43 Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids 2003; 25: 409-417
    CrossrefPubMedGoogle Scholar
  • 44 Lai WK, Kan MY. Homocysteine-induced endothelial dysfunction. Ann Nutr Metab 2015; 67: 1-12
    CrossrefPubMedGoogle Scholar
  • 45 Abu-Farha M, Al-Sabah S, Hammad MM. et al. Prognostic genetic markers for thrombosis in COVID-19 patients: a focused analysis on D-dimer, homocysteine and thromboembolism. Front Pharmacol 2020; 11: 587451
    CrossrefPubMedGoogle Scholar
  • 46 Wang L, Niu H, Zhang J. Homocysteine induces mitochondrial dysfunction and oxidative stress in myocardial ischemia/reperfusion injury through stimulating ROS production and the ERK1/2 signaling pathway. Exp Ther Med 2020; 20: 938-944
    CrossrefPubMedGoogle Scholar
  • 47 Long Y, Zhen X, Zhu F. et al. Hyperhomocysteinemia exacerbates cisplatin-induced acute kidney injury. Int J Biol Sci 2017; 13: 219-231
    CrossrefPubMedGoogle Scholar
  • 48 Jacques PF, Rosenberg IH, Rogers G. et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third national health and nutrition examination survey. Am J Clin Nutr 1999; 69: 482-489
    CrossrefPubMedGoogle Scholar
  • 49 Albert MA, Glynn RJ, Buring JE. et al. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 2007; 99: 1246-1251
    CrossrefPubMedGoogle Scholar
  • 50 Tu W, Yan F, Chao B. et al. Status of hyperhomocysteinemia in China: results from the China stroke high-risk population screening program, 2018. Front Med 2021; 15: 903-912
    CrossrefPubMedGoogle Scholar
  • 51 Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet 2015; 58: 1-10
    CrossrefPubMedGoogle Scholar